TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell

This is an investigational allogeneic CAR-T cell therapy developed by the Chinese PLA General Hospital for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). The therapy utilizes T cells from healthy donors that are genetically modified using CRISPR-Cas9 to knock out the **SPPL3** (Signal peptide peptidase-like 3) gene, also referred to as **Power3**. Unlike most allogeneic CAR-T products that require the knockout of the T-cell receptor (TCR) to prevent graft-versus-host disease (GvHD), this "TCR reserved" approach maintains the native TCR. The SPPL3 knockout facilitates glycan-mediated immune evasion, allowing the allogeneic cells to avoid host T-cell-mediated rejection and persist longer without inducing typical GvHD. The cells are further engineered to express a chimeric antigen receptor (CAR) targeting the **CD19** antigen, enabling the targeted destruction of malignant B cells.

Other names

Power3 (SPPL3) Knock-out Allogeneic CD19 CAR-TTCR-reserved Power3-deleted allogenic CAR T cellsATHENA CAR-T